<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03120637</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Septic Shock-01</org_study_id>
    <nct_id>NCT03120637</nct_id>
  </id_info>
  <brief_title>Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue</brief_title>
  <acronym>CRuMBS</acronym>
  <official_title>Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue in Sepsis: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mortality rates associated septic shock remains unacceptably high, around 20-50%, with
      refractory hypotension in half of these patients. Widespread vasodilatation involves the
      activation of the soluble intracellular enzyme guanylate cyclase (GC) by nitric oxide (NO),
      resulting in the production of cyclic guanosine monophosphate (cGMP). Initially discovered as
      an endothelium-derived relaxing factor in blood vessels, NO is made by the enzyme nitric
      oxide synthase (NOS). It has been suggested that the inhibition of NO generation might be a
      treatment option for sepsis and septic shock. Methylene blue (MB) is a dye that easily
      crosses cell membranes, inhibits iNOS, and is capable of inhibiting the GC enzyme in vascular
      smooth muscle cells.Early use of MB can block the progressive decrease in systemic vascular
      resistance of patients unresponsive to noradrenaline and mitigate the need for prolonged
      vasoconstrictor use. The investigators propose to study the effect of methylene blue on
      cirrhotic adults with sepsis, with refractory vasoplegia unresponsive to maximum doses of
      noradrenaline and vasopressin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">January 10, 2018</completion_date>
  <primary_completion_date type="Actual">January 10, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival in both groups</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Vascular Resistance</measure>
    <time_frame>6 hours</time_frame>
    <description>Change in SVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial Pressure</measure>
    <time_frame>6 hours</time_frame>
    <description>Improvement in MAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of vasopressor dose of 20 percent from time of start of test drug.</measure>
    <time_frame>6 hours</time_frame>
    <description>Effect on decreasing vasopressor doses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Septic Shock</condition>
  <condition>Vasoplegia</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Refractory Shock</condition>
  <arm_group>
    <arm_group_label>Methylene Blue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylene Blue intravenous route, 2 mg/kg Loading Dose over 30 minutes, followed by 0.5 mg/kg/hr for 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <arm_group_label>Methylene Blue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (&gt;18 years )

          2. Refractory septic shock (Noradrenaline &gt;0.5mcg/kg/mt )

        Exclusion Criteria:

          1. Declined consent

          2. Pregnancy

          3. Less than 18 years old

          4. Immunosuppressant patients (e.g. on steroid medication, active anti-cancer
             chemotherapeutic agent, etc.)

          5. Glucose-6-phosphate dehydrogenase deficiency

          6. Medication of Serotonin modulator/SSRI

          7. Pre-existing Pulmonary Hypertension

          8. CKD-Stage IV/V

          9. Patients with GI bleed

         10. Patients on DNR

         11. Patients declared Brain dead
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karthik Ponnappan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liver Coma ICU, Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Bassi E, Park M, Azevedo LC. Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract. 2013;2013:654708. doi: 10.1155/2013/654708. Epub 2013 Sep 15. Review.</citation>
    <PMID>24151551</PMID>
  </results_reference>
  <results_reference>
    <citation>Park BK, Shim TS, Lim CM, Lee SD, Kim WS, Kim DS, Kim WD, Koh Y. The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock. Korean J Intern Med. 2005 Jun;20(2):123-8.</citation>
    <PMID>16134766</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbj√∏rnsson B, Nedashkovsky EV, Bjertnaes LJ. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001 Oct;29(10):1860-7.</citation>
    <PMID>11588440</PMID>
  </results_reference>
  <results_reference>
    <citation>Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002 Dec;30(6):755-62.</citation>
    <PMID>12500513</PMID>
  </results_reference>
  <results_reference>
    <citation>Juffermans NP, Vervloet MG, Daemen-Gubbels CR, Binnekade JM, de Jong M, Groeneveld AB. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide. 2010 May 15;22(4):275-80. doi: 10.1016/j.niox.2010.01.006. Epub 2010 Jan 28.</citation>
    <PMID>20109575</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2017</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methylene Blue</keyword>
  <keyword>Septic Shock</keyword>
  <keyword>Vasoplegia</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Vasoplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

